Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
North America Canada United States

Canada Counters Drug Shortages With Export Bans

  • News

Executive Summary

Canada has announced new restrictions on exports to help mitigate the impact of measures in the US to lower medicine prices there.

You may also be interested in...



Drug Importation: Biden Response To PhRMA Suit Highlights Infeasibility Of Trump-Era Rule

Biden administration asks court to dismiss PhRMA’s lawsuit against Trump-era pathway for drug importation from Canada because FDA has not yet cleared any Section 804 Importation Programs (SIPs). The brief outlines the high hurdles to getting a SIP approved and Canada’s opposition to the programs. It's not clear if the Biden team plans another more feasible route to drug importation.

US Allows Imports To Lower Drug Costs

With the aim of lowering prices and improving access to certain prescription drugs, the US FDA and HHS have decided to allow imports from Canada. To enable this, the FDA has finalized the rule allowing importation and issued accompanying guidance.

Novo Nordisk Hit With UK Industry Association Suspension Over Weight Loss Drug Promotion

Novo Nordisk has been hit by a serious sanction in the UK after having been found to effectively pay pharmacists to promote Saxenda.

Table

View full table

Topics

Tags:
North America Canada United States
Latest Headlines

UK’s Revamped Clinical Trials Framework To Offer Faster Application Review Timelines Than EU

Australia To Seek Stakeholder Input On Terms Of HTA Review

A Milestone Moment For Pharmacogenomics: US FDA Ready To Drop ‘Voluntary’ Program

Electronic Records: US FDA Updates Guidelines On Use In Clinical Investigations

See All
UsernamePublicRestriction

Register

PS143388

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By